Eisai

Eisai, BioArctic's partner, is responsible for the clinical development and commercialization of Leqembi globally. The priority review in China and the potential approval of the subcutaneous formulation will enhance Eisai's market position and revenue potential for Leqembi.

Eisai has secured exclusive commercialization rights for serplulimab in Japan, expanding its oncology portfolio and potentially increasing future revenue through sales of the anti-PD-1 antibody. Eisai will make an upfront payment and additional milestone payments and royalties to Shanghai Henlius Biotech, Inc.

Eisai, BioArctic's partner, will present extensive data on lecanemab's real-world efficacy and safety, as well as four-year data from the Clarity AD Open-Label Extension trial. Eisai is responsible for the global commercialization of lecanemab, and positive data presentations could further boost its market position.

Eisai, BioArctic's partner, is responsible for the global commercialization of Lecanemab. They completed rolling sBLA submission for subcutaneous initiation treatment in the US, secured approvals in Brazil, Canada, and the United Kingdom, and submitted applications in Japan and China. Eisai is steadily progressing toward achieving their full-year sales forecast for Lecanemab.

Eisai sells lecanemab (Leqembi) in partnership with Biogen. The critical review by Cochrane could lead to a decline in Leqembi's market acceptance and Eisai's financial outlook.